Vera Therapeutics Inc Cl A (VERA)

Apr 3, 2025, 8:00 AM EDT - 16 hours ago

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Mar 11, 2025, 4:28 PM EDT - 23 days ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 27, 2025, 8:00 AM EST - 5 weeks ago

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:25 AM EST - 5 weeks ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 22, 2025, 6:46 AM EST - 2 months ago

Top 3 Health Care Stocks That Could Blast Off This Quarter

RDNT VKTX

Jan 7, 2025, 4:05 PM EST - 3 months ago

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Nov 8, 2024, 4:05 PM EST - 5 months ago

Vera Therapeutics to Participate at Upcoming Investor Conferences

Oct 29, 2024, 8:21 PM EDT - 5 months ago

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Oct 28, 2024, 5:37 PM EDT - 5 months ago

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Oct 28, 2024, 10:33 AM EDT - 5 months ago

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

Oct 26, 2024, 7:30 PM EDT - 5 months ago

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Oct 4, 2024, 1:45 PM EDT - 6 months ago

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Oct 2, 2024, 6:30 AM EDT - 6 months ago

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Oct 2, 2024, 6:30 AM EDT - 6 months ago

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Sep 3, 2024, 7:49 AM EDT - 7 months ago

Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says

ADBE CZR KYTX

Aug 8, 2024, 8:00 AM EDT - 8 months ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Jul 22, 2024, 8:52 AM EDT - 9 months ago

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Jun 11, 2024, 4:01 PM EDT - 10 months ago

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Jun 7, 2024, 4:05 PM EDT - 10 months ago

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024, 8:00 AM EDT - 11 months ago

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

May 25, 2024, 9:40 AM EDT - 11 months ago

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

May 9, 2024, 8:00 AM EDT - 11 months ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Mar 20, 2024, 7:30 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 4:20 PM EST - 1 year ago

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Feb 2, 2024, 8:00 AM EST - 1 year ago

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 1, 2024, 4:05 PM EST - 1 year ago

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Jan 29, 2024, 11:50 PM EST - 1 year ago

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Jan 25, 2024, 6:30 AM EST - 1 year ago

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Jan 8, 2024, 8:01 AM EST - 1 year ago

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D.

Dec 27, 2023, 8:00 AM EST - 1 year ago

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Nov 9, 2023, 8:00 AM EST - 1 year ago

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Nov 4, 2023, 10:00 AM EDT - 1 year ago

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

Oct 30, 2023, 8:00 AM EDT - 1 year ago

Vera Therapeutics Scheduled to Present at November Investor Conferences

Oct 13, 2023, 10:22 AM EDT - 1 year ago

Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Aug 17, 2023, 5:47 PM EDT - 1 year ago

Vera Therapeutics' Promising Atacicept Drug Targets IgAN

Aug 10, 2023, 8:00 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results

Jul 4, 2023, 9:42 AM EDT - 1 year ago

Vera: New Kidney Data, May Be A Potential Next Big Pharma M&A Target

Jul 3, 2023, 1:39 PM EDT - 1 year ago

Vera: Repurposed Molecule Program Does Not Impress

Jun 17, 2023, 10:10 AM EDT - 1 year ago

Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

Jun 15, 2023, 4:44 PM EDT - 1 year ago

Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN

Jun 12, 2023, 3:40 PM EDT - 1 year ago

Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts say

NVS TVTX

Jun 8, 2023, 8:00 AM EDT - 1 year ago

Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference

Jun 7, 2023, 8:00 AM EDT - 1 year ago

Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)

May 11, 2023, 7:30 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results

Apr 26, 2023, 12:15 AM EDT - 2 years ago

Strong Small-Cap Insider Buys: Q1 2023

AAT ABBV BY CCB CCO CMP ENVX

Mar 28, 2023, 7:30 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 1, 2023, 4:01 PM EST - 2 years ago

Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

Jan 30, 2023, 6:00 AM EST - 2 years ago

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

Jan 26, 2023, 8:00 AM EST - 2 years ago

Innocoll Holdings Ltd. Appoints Kimball Hall as Chief Executive Officer